Tim Clackson
Xilio Therapeutics (United States) · 212 works · 16,834 citations · h-index 54
Top works
- A Hot Spot of Binding Energy in a Hormone-Receptor Interface
- Making antibody fragments using phage display libraries
- Direct clone characterization from plaques and colonies by the polymerase chain reaction
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- By–Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling
- A humanized system for pharmacologic control of gene expression
- Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML
- Redesigning an FKBP–ligand interface to generate chemical dimerizers with novel specificity
- A versatile synthetic dimerizer for the regulation of protein–protein interactions
- Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity
- In vitro selection from protein and peptide libraries
- Mutations of the Growth Hormone Receptor in Children with Idiopathic Short Stature
- Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase
- Regulation of Protein Secretion Through Controlled Aggregation in the Endoplasmic Reticulum
- Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis Screen
- Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant
- The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
- Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models